Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68-0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
Miller R, Santangelo T, Forghani-Arani F, Rusthoven C, Chen Y, Castillo E, et al [Guerrero T] Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial. Radiother Oncol. 2022 Jun;171:22-24. doi: 10.1016/j.radonc.2022.04.003. PMID: 35413391.